Bypassing the need for pre-sensitization of cancer cells for anticancer TRAIL therapy with secretion of novel cell penetrable form of Smac from hA-MSCs as cellular delivery vehicle

Tumor Biology

Volumn 36, Issue 6, 2015, Pages 4213-4221

  Khorashadizadeh, Mohsen ^a   Soleimani, Masoud ^b   Khanahmad, Hossein ^c   Fallah, Ali ^d   Naderi, Mahmood ^e,f   Khorramizadeh, Mohammadreza ^a,g  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TARBIAT MODARES UNIVERSITY   (Iran)

^c ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d Mede Bioeconomy Company   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f STEM CELL TECHNOLOGY RESEARCH CENTER   (Iran)

^g TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Breast cancer; Mesenchymal stem cells; Smac; TRAIL; XIAP

Indexed keywords

SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; DIABLO PROTEIN, HUMAN; MITOCHONDRIAL PROTEIN; SIGNAL PEPTIDE; TNFSF10 PROTEIN, HUMAN; X LINKED INHIBITOR OF APOPTOSIS; XIAP PROTEIN, HUMAN;

ADIPOSE DERIVED STEM CELL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELLULAR SECRETION; DRUG CYTOTOXICITY; DRUG SENSITIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LENTIVIRINAE; MCF 7 CELL LINE; MESENCHYMAL STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRAL GENE DELIVERY SYSTEM; ADIPOSE TISSUE; BREAST NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY;

ADIPOSE TISSUE; APOPTOSIS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MCF-7 CELLS; MESENCHYMAL STROMAL CELLS; MITOCHONDRIAL PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84938979765     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3058-2     Document Type: Article

References (20)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30. doi:10.3322/caac.21166.
2. Gonzalvez F, Ashkenazi A. New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene. 2010;29(34):4752–65. doi:10.1038/onc.2010.221.
3. Stuckey DW, Shah K. TRAIL on trial: preclinical advances in cancer therapy. Trends Mol Med. 2013;19(11):685–94. doi:10.1016/j.molmed.2013.08.007.
4. Lee TJ, Lee JT, Park JW, Kwon TK. Acquired TRAIL resistance in human breast cancer cells are caused by the sustained cFLIP(L) and XIAP protein levels and ERK activation. Biochem Biophys Res Commun. 2006;351(4):1024–30. doi:10.1016/j.bbrc.2006.10.163.
5. Srinivasula SM, Hegde R, Saleh A, Datta P, Shiozaki E, Chai J, et al. A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature. 2001;410(6824):112–6. doi:10.1038/35065125.
6. Fandy TE, Shankar S, Srivastava RK. Smac/DIABLO enhances the therapeutic potential of chemotherapeutic drugs and irradiation, and sensitizes TRAIL-resistant breast cancer cells. Mol Cancer. 2008;7:60. doi:10.1186/1476-4598-7-60.
7. Bockbrader KM, Tan M, Sun Y. A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells. Oncogene. 2005;24(49):7381–8. doi:10.1038/sj.onc.1208888.
8. Mohr A, Albarenque SM, Deedigan L, Yu R, Reidy M, Fulda S, et al. Targeting of XIAP combined with systemic mesenchymal stem cell-mediated delivery of sTRAIL ligand inhibits metastatic growth of pancreatic carcinoma cells. Stem Cells. 2010;28(11):2109–20. doi:10.1002/stem.533.
9. Ryu CH, Park KY, Kim SM, Jeong CH, Woo JS, Hou Y, et al. Valproic acid enhances anti-tumor effect of mesenchymal stem cell mediated HSV-TK gene therapy in intracranial glioma. Biochem Biophys Res Commun. 2012;421(3):585–90. doi:10.1016/j.bbrc.2012.04.050.
10. Ling X, Marini F, Konopleva M, Schober W, Shi Y, Burks J, et al. Mesenchymal stem cells overexpressing IFN-beta inhibit breast cancer growth and metastases through Stat3 signaling in a syngeneic tumor model. Cancer Microenviron: Off J Int Cancer Microenviron Soc. 2010;3(1):83–95. doi:10.1007/s12307-010-0041-8.
11. Ren C, Kumar S, Chanda D, Chen J, Mountz JD, Ponnazhagan S. Therapeutic potential of mesenchymal stem cells producing interferon-alpha in a mouse melanoma lung metastasis model. Stem Cells. 2008;26(9):2332–8. doi:10.1634/stemcells. 2008-0084.
12. Grisendi G, Bussolari R, Cafarelli L, Petak I, Rasini V, Veronesi E, et al. Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy. Cancer Res. 2010;70(9):3718–29. doi:10.1158/0008-5472.CAN-09-1865.
13. Loebinger MR, Eddaoudi A, Davies D, Janes SM. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res. 2009;69(10):4134–42. doi:10.1158/0008-5472.CAN-08-4698.
14. Shen Y, Yu W, Hay JG, Sauthoff H. Expressed cell-penetrating peptides can induce a bystander effect, but passage through the secretory pathway reduces protein transduction activity. Mol Ther: J Am Soc Gene Ther. 2011;19(5):903–12. doi:10.1038/mt.2010.283.
15. Barde I, Salmon P, Trono D. Production and titration of lentiviral vectors. Current protocols in neuroscience / editorial board, Jacqueline N Crawley [et al.]. 2010;Chapter 4:Unit 4 21. doi:10.1002/0471142301.ns0421s53
16. Wu X, He Y, Falo Jr LD, Hui KM, Huang L. Regression of human mammary adenocarcinoma by systemic administration of a recombinant gene encoding the hFlex-TRAIL fusion protein. Mol Ther: J Am Soc Gene Ther. 2001;3(3):368–74. doi:10.1006/mthe.2001.0280.
17. Francis MP, Sachs PC, Elmore LW, Holt SE. Isolating adipose-derived mesenchymal stem cells from lipoaspirate blood and saline fraction. Organogenesis. 2010;6(1):11–4.
18. Nadri S, Soleimani M. Isolation murine mesenchymal stem cells by positive selection. In Vitro Cell Dev Biol Anim. 2007;43(8–9):276–82. doi:10.1007/s11626-007-9041-5.
19. Rahman M, Davis SR, Pumphrey JG, Bao J, Nau MM, Meltzer PS, et al. TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. Breast Cancer Res Treat. 2009;113(2):217–30. doi:10.1007/s10549-008-9924-5.
20. Secchiero P, Melloni E, Corallini F, Beltrami AP, Alviano F, Milani D, et al. Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells. Stem Cells. 2008;26(11):2955–63. doi:10.1634/stemcells. 2008-0512.